Methods of treating a tumor using an anti-PD-1 antibody

Patent metadata

Field	Value
Publication number	US-12227576-B2
Application number	US-202318161713-A
Country	US
Kind code	B2
Filing date	Jan 30, 2023
Priority date	Jun 1, 2017
Publication date	Feb 18, 2025
Grant date	Feb 18, 2025

Abstract

This disclosure provides a method for treating a subject afflicted with tumor, which method comprises administering to the subject an antibody or an antigen-binding portion thereof that specifically binds to a Programmed Death-1 (PD-1) receptor and inhibits PD-1 activity. In some embodiments, the tumor is derived from a non-small cell lung cancer (NSCLC). In some embodiments, the tumor expresses Programmed Death Ligand 1. In some embodiments, the subject carries a wild-type STK11 gene.

First claim

What is claimed is:

1. A method of treating a subject afflicted with a tumor derived from a lung cancer comprising, (i) determining a mutation status of an STK11 gene in the subject; and (ii) administering to the subject an antibody or an antigen-binding portion thereof that binds specifically to a Programmed Death-1 (PD-1) receptor and inhibits PD-1 activity (“anti-PD-1 antibody”), wherein the subject is identified as having (i)_a wild-type STK11 gene and (ii) a mutated marker gene comprising PTPRD, CUBN, or a combination thereof; and wherein the tumor exhibits a diffuse membranous PD-L1 expression.

2. The method of claim 1 , wherein the marker gene comprises a non-synonymous mutation, a nonsense, a frameshift, or a splicing mutation.

3. The method of claim 1 , further comprising detecting PD-L1 expression in the tumor prior to the administration of the anti-PD-1 antibody.

4. The method of claim 1 , wherein the tumor has a tumor mutational burden (TMB) status that is a high TMB.

5. The method of claim 4 , wherein the tumor TMB status is determined by sequencing nucleic acids in the tumor and identifying a genomic alteration in the sequenced nucleic acids, wherein the genomic alteration comprises one or more alterations comprising a somatic mutation, a non-synonymous mutation, a missense mutation, a base pair substitution, a base pair insertion, a base pair deletion, a copy number alteration (CNAs), a gene rearrangement, or any combination thereof.

6. The method of claim 1 , wherein the tumor exhibits high inflammation.

7. The method of claim 1 , wherein the anti-PD-1 antibody comprises nivolumab, pembrolizumab, PDR001, MEDI-0680, cemiplimab, JS001, BGB-A317, INCSHR1210, TSR-042, GLS-010, AM-0001, STI-1110, AGEN2034, MGA012, or IBI308.

8. The method of claim 1 , wherein the anti-PD-1 antibody is administered at a dose ranging from at least about 0.1 mg/kg to at least about 10.0 mg/kg body weight once about every 1, 2, or 3 weeks.

9. The method of claim 1 , wherein the anti-PD-1 antibody is administered at a flat dose of about 240 mg or about 480 mg about once every 1, 2, 3, or 4 weeks.

10. The method of claim 1 , wherein the anti-PD-1 antibody comprises nivolumab.

11. The method of claim 10 , wherein the anti-PD-1 antibody is administered at a flat dose of about 240 mg once about every 2 weeks.

12. The method of claim 10 , wherein the anti-PD-1 antibody is administered at a flat dose of about 360 mg once about every 3 weeks.

13. The method of claim 10 , wherein the anti-PD-1 antibody is administered at a flat dose of about 480 mg once about every 4 weeks.

14. The method of claim 1 , wherein the anti-PD-1 antibody comprises pembrolizumab.

15. The method of claim 14 , wherein the anti-PD-1 antibody is administered at a flat dose of about 200 mg once about every 3 weeks.

16. The method of claim 1 , wherein the tumor is recurrent.

17. The method of claim 1 , wherein the subject has progressed during or after prior platinum-based doublet chemotherapy.

18. The method of claim 1 , wherein the tumor is previously untreated.

19. The method of claim 1 , wherein the tumor is a stage IV NSCLC.

20. The method of claim 1 , wherein the subject is further identified as having a mutated marker gene comprising KRAS, TP53, CDKN2A, HERC1, or any combination thereof.

Assignees

• Bristol Myers Squibb Co

Inventors

• Edwards Robin
• Geese William J
• Greenawalt Danielle M

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• A61K2039/505

  comprising antibodies · CPC title

• C07K16/2818 Primary

  against CD28 or CD152 · CPC title